French specialist pharmaceutical database and software company Cegedim is to buy its US-based rivals Dendrite for $751 million.Dendrite's board of …
Thousands more patients are set to be enrolled on clinical trials in primary care in the UK, thanks to the …
Novartis new hypertension drug Exforge has been launched in the UK, promising to help more patients lower their blood pressure …
Pfizer has gained a court injunction ordering the withdrawal of a generic version of its top-seller Lipitor (atorvastatin).Indian generics company …
Swiss specialist pharma company Actelion saw sales revenue rise 43% in 2006 thanks to rapid growth in its two products, …
Shire and New River Pharmaceuticals have been given the green light by the FDA to market anti-ADHD drug Vyvanse. Shire, …
The Healthcare Communications Association (HCA), which aims to promote excellence and best practice within pharmaceutical industry communications, has reached its …
The Office of Fair Trading wants to reform the way prescription medicines are priced to reflect the benefits they bring …
In December 2006, the official report on the Northwick Park incident was published. Although not the end of the affair, …
The British Medical Association has branded as "nonsensical" the situation whereby hospitals delay routine operations because of financial problems.The doctors' …
Pfizer has confirmed that it is to submit evidence to a forthcoming inquiry into the workings of NICE.The Commons Health …
Figures show that Sanofi-Aventis continued to grow in 2006, despite its complaints about pressure in the US from generic manufacturers …
A new treatment for HIV is to be fast-tracked in Europe and the US.Pfizer's new compound maraviroc is to receive …
The EU has granted London-based Ark Therapeutics £1.65 million to fund research into using insect-derived viruses for producing genetic medicines.Ark …
A collaboration between GlaxoSmithKline, Boehringer Ingelheim, Pfizer and East Lincolnshire PCT has been heralded as the future of healthcare in …
Sanofi-Aventis' obesity treatment Acomplia (rimonabant) will be among the drugs appraised by NICE in its latest works programme. With an …
European biotech companies ThromboGenics and BioInvent are to start a phase I trial of a new drug which could prove …
It is universally acknowledged, almost to the point of cliche, that pharmaceutical companies operate in a highly competitive environment. Ensuring …
GlaxoSmithKline is planning to launch five new products in 2007, bringing to an end a long period for the company …
A 60% increase in sales of its cholesterol drugs franchise has helped Schering-Plough to post strong growth for 2006.Ezetrol and …